Item 8.01. Other Events
On June 30, 2008, Myriad Genetics, Inc. (the Company) announced results of its 18-month Phase 3 study of Flurizan (tarenflurbil) in patients with mild Alzheimer's disease. The study did not achieve statistical significance on either of its primary endpoints -- cognition and activities of daily living. As a result the Company is discontinuing all ongoing Flurizan clinical studies, including its global Phase 3 trial.
The press release is being filed herewith as Exhibit 99.1 and the information contained therein is incorporated by reference into Item 8.01 of this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits
(d) The following exhibit is filed with this report:
Exhibit
Number Description
99.1 The Registrant's press release dated June 30, 2008.
Signature(s)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
|
Myriad Genetics, Inc.
|
||||||
|
Date: July 01, 2008
|
By:
|
/s/ Peter D. Meldrum
|
||||||
|
Peter D. Meldrum
|
||||||||
|
President and Chief Executive Officer
|
||||||||
Exhibit Index
|
Exhibit No.
|
Description
|
|
|
EX-99.1
|
Exhibit 99.1
|